Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score

Results from the SEARCH Database

David E. Kang, Nicholas J. Fitzsimons, Joseph C. Presti, Christopher J. Kane, Martha Kennedy Terris, William J. Aronson, Christopher L. Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: Gleason score 4+3 prostate cancer is associated with worse clinicopathologic outcomes than is Gleason score 3+4. Whether the increased risk associated with Gleason score 4+3 disease is equivalent to that of Gleason score 4+4 or greater is unclear. Methods: We reviewed the data from two separate cohorts pulled from the Shared Equal Access Regional Cancer Hospital database. The first consisted of 374 men with biopsy Gleason score 3+4 or greater disease and the second of 636 men with radical prostatectomy (RP) Gleason score 3+4 or greater disease. We estimated the odds ratios of unfavorable surgical pathologic findings for the biopsy Gleason score categories using logistic regression analysis. Using a Cox proportional hazards regression model, we estimated the relative risk of biochemical progression associated with each biopsy and RP Gleason score category. Results: In the biopsy Gleason score cohort, a Gleason score of 4+3 was associated with an increased risk of extracapsular extension (P = 0.01) and seminal vesicle invasion (P <0.001) relative to a biopsy Gleason score of 3+4. A biopsy Gleason score of 4+3 was associated with a similar risk of adverse pathologic findings relative to a biopsy Gleason score of 4+4 or greater (all P >0.10), except for higher grade pathologic tumors among men with a biopsy Gleason score of 4+4 or more (P = 0.001). After adjusting for multiple clinical characteristics, a biopsy Gleason score of 4+3 was associated with an increased recurrence risk relative to a biopsy Gleason score of 3+4 (P = 0.001), but a similar progression risk as that for a biopsy Gleason score of 4+4 or more (P = 0.53). In the RP Gleason cohort, and after adjustment for multiple clinicopathologic features, an RP Gleason score of 4+3 was associated with increased progression risk relative to an RP Gleason score of 3+4 (P = 0.03), but similar progression risk as that for an RP Gleason score of 4+4 or more (P = 0.24). Conclusions: In a multicenter database using pooled data from multiple pathologists, Gleason scores 4+3 and 4+4 or more exhibited similar clinicopathologic outcomes.

Original languageEnglish (US)
Pages (from-to)277-282
Number of pages6
JournalUrology
Volume70
Issue number2
DOIs
StatePublished - Aug 1 2007

Fingerprint

Neoplasm Grading
Databases
Neoplasms
Prostatectomy
Biopsy
Cancer Care Facilities
Seminal Vesicles

ASJC Scopus subject areas

  • Urology

Cite this

Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score : Results from the SEARCH Database. / Kang, David E.; Fitzsimons, Nicholas J.; Presti, Joseph C.; Kane, Christopher J.; Terris, Martha Kennedy; Aronson, William J.; Amling, Christopher L.; Freedland, Stephen J.

In: Urology, Vol. 70, No. 2, 01.08.2007, p. 277-282.

Research output: Contribution to journalArticle

Kang, David E. ; Fitzsimons, Nicholas J. ; Presti, Joseph C. ; Kane, Christopher J. ; Terris, Martha Kennedy ; Aronson, William J. ; Amling, Christopher L. ; Freedland, Stephen J. / Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score : Results from the SEARCH Database. In: Urology. 2007 ; Vol. 70, No. 2. pp. 277-282.
@article{d9378fd4176a4312bed540ce89e6a5c8,
title = "Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score: Results from the SEARCH Database",
abstract = "Objectives: Gleason score 4+3 prostate cancer is associated with worse clinicopathologic outcomes than is Gleason score 3+4. Whether the increased risk associated with Gleason score 4+3 disease is equivalent to that of Gleason score 4+4 or greater is unclear. Methods: We reviewed the data from two separate cohorts pulled from the Shared Equal Access Regional Cancer Hospital database. The first consisted of 374 men with biopsy Gleason score 3+4 or greater disease and the second of 636 men with radical prostatectomy (RP) Gleason score 3+4 or greater disease. We estimated the odds ratios of unfavorable surgical pathologic findings for the biopsy Gleason score categories using logistic regression analysis. Using a Cox proportional hazards regression model, we estimated the relative risk of biochemical progression associated with each biopsy and RP Gleason score category. Results: In the biopsy Gleason score cohort, a Gleason score of 4+3 was associated with an increased risk of extracapsular extension (P = 0.01) and seminal vesicle invasion (P <0.001) relative to a biopsy Gleason score of 3+4. A biopsy Gleason score of 4+3 was associated with a similar risk of adverse pathologic findings relative to a biopsy Gleason score of 4+4 or greater (all P >0.10), except for higher grade pathologic tumors among men with a biopsy Gleason score of 4+4 or more (P = 0.001). After adjusting for multiple clinical characteristics, a biopsy Gleason score of 4+3 was associated with an increased recurrence risk relative to a biopsy Gleason score of 3+4 (P = 0.001), but a similar progression risk as that for a biopsy Gleason score of 4+4 or more (P = 0.53). In the RP Gleason cohort, and after adjustment for multiple clinicopathologic features, an RP Gleason score of 4+3 was associated with increased progression risk relative to an RP Gleason score of 3+4 (P = 0.03), but similar progression risk as that for an RP Gleason score of 4+4 or more (P = 0.24). Conclusions: In a multicenter database using pooled data from multiple pathologists, Gleason scores 4+3 and 4+4 or more exhibited similar clinicopathologic outcomes.",
author = "Kang, {David E.} and Fitzsimons, {Nicholas J.} and Presti, {Joseph C.} and Kane, {Christopher J.} and Terris, {Martha Kennedy} and Aronson, {William J.} and Amling, {Christopher L.} and Freedland, {Stephen J.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.urology.2007.03.059",
language = "English (US)",
volume = "70",
pages = "277--282",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score

T2 - Results from the SEARCH Database

AU - Kang, David E.

AU - Fitzsimons, Nicholas J.

AU - Presti, Joseph C.

AU - Kane, Christopher J.

AU - Terris, Martha Kennedy

AU - Aronson, William J.

AU - Amling, Christopher L.

AU - Freedland, Stephen J.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Objectives: Gleason score 4+3 prostate cancer is associated with worse clinicopathologic outcomes than is Gleason score 3+4. Whether the increased risk associated with Gleason score 4+3 disease is equivalent to that of Gleason score 4+4 or greater is unclear. Methods: We reviewed the data from two separate cohorts pulled from the Shared Equal Access Regional Cancer Hospital database. The first consisted of 374 men with biopsy Gleason score 3+4 or greater disease and the second of 636 men with radical prostatectomy (RP) Gleason score 3+4 or greater disease. We estimated the odds ratios of unfavorable surgical pathologic findings for the biopsy Gleason score categories using logistic regression analysis. Using a Cox proportional hazards regression model, we estimated the relative risk of biochemical progression associated with each biopsy and RP Gleason score category. Results: In the biopsy Gleason score cohort, a Gleason score of 4+3 was associated with an increased risk of extracapsular extension (P = 0.01) and seminal vesicle invasion (P <0.001) relative to a biopsy Gleason score of 3+4. A biopsy Gleason score of 4+3 was associated with a similar risk of adverse pathologic findings relative to a biopsy Gleason score of 4+4 or greater (all P >0.10), except for higher grade pathologic tumors among men with a biopsy Gleason score of 4+4 or more (P = 0.001). After adjusting for multiple clinical characteristics, a biopsy Gleason score of 4+3 was associated with an increased recurrence risk relative to a biopsy Gleason score of 3+4 (P = 0.001), but a similar progression risk as that for a biopsy Gleason score of 4+4 or more (P = 0.53). In the RP Gleason cohort, and after adjustment for multiple clinicopathologic features, an RP Gleason score of 4+3 was associated with increased progression risk relative to an RP Gleason score of 3+4 (P = 0.03), but similar progression risk as that for an RP Gleason score of 4+4 or more (P = 0.24). Conclusions: In a multicenter database using pooled data from multiple pathologists, Gleason scores 4+3 and 4+4 or more exhibited similar clinicopathologic outcomes.

AB - Objectives: Gleason score 4+3 prostate cancer is associated with worse clinicopathologic outcomes than is Gleason score 3+4. Whether the increased risk associated with Gleason score 4+3 disease is equivalent to that of Gleason score 4+4 or greater is unclear. Methods: We reviewed the data from two separate cohorts pulled from the Shared Equal Access Regional Cancer Hospital database. The first consisted of 374 men with biopsy Gleason score 3+4 or greater disease and the second of 636 men with radical prostatectomy (RP) Gleason score 3+4 or greater disease. We estimated the odds ratios of unfavorable surgical pathologic findings for the biopsy Gleason score categories using logistic regression analysis. Using a Cox proportional hazards regression model, we estimated the relative risk of biochemical progression associated with each biopsy and RP Gleason score category. Results: In the biopsy Gleason score cohort, a Gleason score of 4+3 was associated with an increased risk of extracapsular extension (P = 0.01) and seminal vesicle invasion (P <0.001) relative to a biopsy Gleason score of 3+4. A biopsy Gleason score of 4+3 was associated with a similar risk of adverse pathologic findings relative to a biopsy Gleason score of 4+4 or greater (all P >0.10), except for higher grade pathologic tumors among men with a biopsy Gleason score of 4+4 or more (P = 0.001). After adjusting for multiple clinical characteristics, a biopsy Gleason score of 4+3 was associated with an increased recurrence risk relative to a biopsy Gleason score of 3+4 (P = 0.001), but a similar progression risk as that for a biopsy Gleason score of 4+4 or more (P = 0.53). In the RP Gleason cohort, and after adjustment for multiple clinicopathologic features, an RP Gleason score of 4+3 was associated with increased progression risk relative to an RP Gleason score of 3+4 (P = 0.03), but similar progression risk as that for an RP Gleason score of 4+4 or more (P = 0.24). Conclusions: In a multicenter database using pooled data from multiple pathologists, Gleason scores 4+3 and 4+4 or more exhibited similar clinicopathologic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=34548461739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548461739&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.03.059

DO - 10.1016/j.urology.2007.03.059

M3 - Article

VL - 70

SP - 277

EP - 282

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -